Cargando…

Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal?

BACKGROUND: In France, the colorectal cancer organised screening programme uses the faecal immunological test. A positive test ⩾30 μg Hb/g of stool leads to a colonoscopy for identification of potential colorectal lesions. Cut-off values vary from 20 to 47 μg Hb/g of stool in Western countries. We h...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellat, Anna, Deyra, Jacques, Husson, Marie, Benamouzig, Robert, Coriat, Romain, Chaussade, Stanislas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111528/
https://www.ncbi.nlm.nih.gov/pubmed/33995581
http://dx.doi.org/10.1177/17562848211009716
_version_ 1783690519792058368
author Pellat, Anna
Deyra, Jacques
Husson, Marie
Benamouzig, Robert
Coriat, Romain
Chaussade, Stanislas
author_facet Pellat, Anna
Deyra, Jacques
Husson, Marie
Benamouzig, Robert
Coriat, Romain
Chaussade, Stanislas
author_sort Pellat, Anna
collection PubMed
description BACKGROUND: In France, the colorectal cancer organised screening programme uses the faecal immunological test. A positive test ⩾30 μg Hb/g of stool leads to a colonoscopy for identification of potential colorectal lesions. Cut-off values vary from 20 to 47 μg Hb/g of stool in Western countries. We herein question this threshold’s relevance in a French population and perform a retrospective observational study using the Parisian database between 1 April 2015 and 31 December 2018. METHODS: Rates of participation, numbers of positive faecal immunological test (FIT), detection rates and positive predictive values for advanced adenomas and/or colorectal cancer were determined. Mean positivity values for colorectal lesions were calculated. RESULTS: In our population, there were 4.1% positive tests and 67.6% colonoscopy results available with final reports. Positive predictive value for advanced adenomas and colorectal cancer were 30% [95% confidence interval (CI) 29.8–30.3] and 7.4% (95% CI 7.35–7.52), respectively. The mean positivity value for all positive tests in our population was 101.7 µg Hb/g of stool (95% CI 85–118.3). There were 1136 normal colonoscopies (21.4%) with a mean positivity value of 88.6 μg Hb/g of stool. Following a negative test in a first screening campaign, 40.8% of patients in our population performed a second test with a positivity rate of 1.3% and with the encounter of 81 colorectal cancers. The risk of having a positive test during the second screening campaign and finding advanced colorectal lesions significantly increased (all p < 0.001) when comparing negative FIT results ranging between 15 and 29 μg Hb/g of stool to 0 and 14 μg Hb/g of stool from the previous campaign. CONCLUSION: Using the current positivity threshold, some patients were considered negative with a delay in colorectal cancer diagnosis, suggesting the threshold could be lowered. Also, the mean positivity value for normal colonoscopies was high, raising the question of upper gastrointestinal bleeding.
format Online
Article
Text
id pubmed-8111528
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-81115282021-05-13 Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal? Pellat, Anna Deyra, Jacques Husson, Marie Benamouzig, Robert Coriat, Romain Chaussade, Stanislas Therap Adv Gastroenterol Original Research BACKGROUND: In France, the colorectal cancer organised screening programme uses the faecal immunological test. A positive test ⩾30 μg Hb/g of stool leads to a colonoscopy for identification of potential colorectal lesions. Cut-off values vary from 20 to 47 μg Hb/g of stool in Western countries. We herein question this threshold’s relevance in a French population and perform a retrospective observational study using the Parisian database between 1 April 2015 and 31 December 2018. METHODS: Rates of participation, numbers of positive faecal immunological test (FIT), detection rates and positive predictive values for advanced adenomas and/or colorectal cancer were determined. Mean positivity values for colorectal lesions were calculated. RESULTS: In our population, there were 4.1% positive tests and 67.6% colonoscopy results available with final reports. Positive predictive value for advanced adenomas and colorectal cancer were 30% [95% confidence interval (CI) 29.8–30.3] and 7.4% (95% CI 7.35–7.52), respectively. The mean positivity value for all positive tests in our population was 101.7 µg Hb/g of stool (95% CI 85–118.3). There were 1136 normal colonoscopies (21.4%) with a mean positivity value of 88.6 μg Hb/g of stool. Following a negative test in a first screening campaign, 40.8% of patients in our population performed a second test with a positivity rate of 1.3% and with the encounter of 81 colorectal cancers. The risk of having a positive test during the second screening campaign and finding advanced colorectal lesions significantly increased (all p < 0.001) when comparing negative FIT results ranging between 15 and 29 μg Hb/g of stool to 0 and 14 μg Hb/g of stool from the previous campaign. CONCLUSION: Using the current positivity threshold, some patients were considered negative with a delay in colorectal cancer diagnosis, suggesting the threshold could be lowered. Also, the mean positivity value for normal colonoscopies was high, raising the question of upper gastrointestinal bleeding. SAGE Publications 2021-05-07 /pmc/articles/PMC8111528/ /pubmed/33995581 http://dx.doi.org/10.1177/17562848211009716 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Pellat, Anna
Deyra, Jacques
Husson, Marie
Benamouzig, Robert
Coriat, Romain
Chaussade, Stanislas
Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal?
title Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal?
title_full Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal?
title_fullStr Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal?
title_full_unstemmed Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal?
title_short Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal?
title_sort colorectal cancer screening programme: is the french faecal immunological test (fit) threshold optimal?
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111528/
https://www.ncbi.nlm.nih.gov/pubmed/33995581
http://dx.doi.org/10.1177/17562848211009716
work_keys_str_mv AT pellatanna colorectalcancerscreeningprogrammeisthefrenchfaecalimmunologicaltestfitthresholdoptimal
AT deyrajacques colorectalcancerscreeningprogrammeisthefrenchfaecalimmunologicaltestfitthresholdoptimal
AT hussonmarie colorectalcancerscreeningprogrammeisthefrenchfaecalimmunologicaltestfitthresholdoptimal
AT benamouzigrobert colorectalcancerscreeningprogrammeisthefrenchfaecalimmunologicaltestfitthresholdoptimal
AT coriatromain colorectalcancerscreeningprogrammeisthefrenchfaecalimmunologicaltestfitthresholdoptimal
AT chaussadestanislas colorectalcancerscreeningprogrammeisthefrenchfaecalimmunologicaltestfitthresholdoptimal